Here, we analyzed multiple independent cohorts of patients with NSCLC treated with programmed cell death–1 (PD-1)/PD-L1 inhibitors to identify clinicopathological, genomic, and immunophenotypic correlates of TMB, and to investigate TMB groupings that best discriminate responders from nonresponders to ICIs. The gene discussed is CD274; the disease is non-small cell lung carcinoma.